These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17826096)

  • 1. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
    Sasse BC; Mach UR; Leppaenen J; Calmels T; Stark H
    Bioorg Med Chem; 2007 Dec; 15(23):7258-73. PubMed ID: 17826096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands.
    Saur O; Hackling AE; Perachon S; Schwartz JC; Sokoloff P; Stark H
    Arch Pharm (Weinheim); 2007 Apr; 340(4):178-84. PubMed ID: 17405129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
    Carling RW; Moore KW; Moyes CR; Jones EA; Bonner K; Emms F; Marwood R; Patel S; Patel S; Fletcher AE; Beer M; Sohal B; Pike A; Leeson PD
    J Med Chem; 1999 Jul; 42(14):2706-15. PubMed ID: 10411491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
    Wu X; Chen J; Ji M; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5813-6. PubMed ID: 15501046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
    Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
    J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives.
    Grassmann S; Apelt J; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Arch Pharm (Weinheim); 2004 Oct; 337(10):533-45. PubMed ID: 15476285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
    Chen J; Ding K; Levant B; Wang S
    Bioorg Med Chem Lett; 2006 Jan; 16(2):443-6. PubMed ID: 16290142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands.
    Mach UR; Hackling AE; Perachon S; Ferry S; Wermuth CG; Schwartz JC; Sokoloff P; Stark H
    Chembiochem; 2004 Apr; 5(4):508-18. PubMed ID: 15185375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
    Pettersson F; Pontén H; Waters N; Waters S; Sonesson C
    J Med Chem; 2010 Mar; 53(6):2510-20. PubMed ID: 20155917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
    Lewis TA; Young MA; Arrington MP; Bayless L; Cai X; Collart P; Eckman JB; Ellis JL; Ene DG; Libertine L; Nicolas JM; Scannell RT; Wels BF; Wenberg K; Wypij DM
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5591-4. PubMed ID: 15482930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent dopamine D2 receptor ligands: synthesis and binding properties.
    Kühhorn J; Hübner H; Gmeiner P
    J Med Chem; 2011 Jul; 54(13):4896-903. PubMed ID: 21599022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.
    Liu Z; Chen X; Sun P; Yu L; Zhen X; Zhang A
    Bioorg Med Chem; 2008 Sep; 16(18):8335-8. PubMed ID: 18783955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands.
    Leopoldo M; Lacivita E; Colabufo NA; Berardi F; Perrone R
    J Pharm Pharmacol; 2006 Feb; 58(2):209-18. PubMed ID: 16451749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors.
    Enzensperger C; Müller FK; Schmalwasser B; Wiecha P; Traber H; Lehmann J
    J Med Chem; 2007 Sep; 50(18):4528-33. PubMed ID: 17676831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands.
    Ortega R; Raviña E; Masaguer CF; Areias F; Brea J; Loza MI; López L; Selent J; Pastor M; Sanz F
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1773-8. PubMed ID: 19217777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.